Cancer Gene Therapy Market
Market Insights on Cancer Gene Therapy covering sales outlook, demand forecast & up-to-date key trends
Cancer Gene Therapy Market by Therapy, Indication, Service Provider & Region - Forecast 2022 – 2032
Cancer Gene Therapy Market Outlook (2022-2032)
[300+ Pages Report] The global demand for the cancer gene therapy is expected to increase at a 10.1% CAGR from 2022 to 2032, reaching US$ 2 Bn in 2022. As per Future Market Insights (FMI), the oncolytic virotherapy segment held 49.3% of the overall global cancer gene therapy market in 2021, which is projected to be valued at US$ 5.3 Bn in the year 2032.
|
Data Points |
Market Insights |
|
Cancer Gene Therapy Market Base Year Value (2021) |
US$ 1.9 Bn |
|
Estimated Market Size (2022) |
US$ 2.0 Bn |
|
Projected Market Valuation (2032) |
US$ 5.3 Bn |
|
Value-based CAGR (2022-2032) |
10.1% |
|
Market Share of Top 5 Countries |
74.8% |
The global market of cancer gene therapy accounted for nearly 45.2% of the overall global gene therapy market worth around US$ 4.0 Bn in 2021.
Initially, gene therapy for monogenetic illnesses was popular; however, gene therapy for cancer treatment is growing in popularity. Cancer gene therapy is a method of treating cancer patients by introducing therapeutic DNA into their bodies.
Let us know your requirement to get
100% FREE customization
2017-2021 Cancer Gene Therapy Market Historic Outlook Vs 2022-2032 Forecast
Demand for cancer gene therapy is forecast to increase at a 10.1% CAGR over the forecast period, in comparison to the 7.1% CAGR registered between 2017 to 2021.
Multiple mutations in a single cell cause cancer to spread. Cancer cells infiltrate new cell, have a rapid metabolism, and are constantly altering shape. Surgery, radiation therapy, and chemotherapy are options for cancer treatment. Gene therapy is utilised if the abovementioned treatments do not deliver the intended results.
In gene therapy, a functional gene, also known as therapeutic DNA, is inserted into the cells of a cancer patient to modify metabolism, alter or repair acquired genetic abnormalities, and impart new functions to cells.
For the last two decades, gene therapy has been a hot topic of research. Ten gene therapy products have been authorized for marketing in at least one country as of January 28, 2018. According to recent forecasts, 12 to 14 new gene therapies will be filed for approval in the following few years, with roughly 40 new medicines approved by the end of 2022.
Oncolytic viral therapy, gene transfer, and gene-induced immunotherapy are examples of cancer treatments. Gene therapy can be used in a variety of ways. For instance, replacing missing or defective genes with healthy genes, altering gene regulation, or introducing foreign genes into cells to alter their function or survival.
Electroporation, magnetofection, naked / plasmid vectors, sonoporation, and gene guns are examples of transgene treatment. Gene-induced immunotherapy is projected to dominate the global cancer gene therapy market over the forecast period.
Various organizations are investing heavily in cancer research. For Instance, in October 2017, American Cancer Society (ACS) approved a US$ 39.8 million funding for 78 training and research grants. These grants were awarded to researchers at 57 institutions across the U.S.
This has brought about significant developments in the field of cancer research and has led to further growth in the global oncogene therapy market.
Governments in various underdeveloped nations are actively taking steps to stimulate various research efforts aimed at producing cancer gene therapy and treatment plans to lower mortality and morbidity rates, which will drive the market.
Because of its high success rate in preclinical and clinical trials, cancer gene therapy is gaining prominence. The most popular method of cancer gene therapy is to replace a cancer-causing mutant gene with a healthy copy of the gene.
What Are The Key Opportunities For Cancer Gene Therapy Market Players?
Rising success rates of novel medicines and ethical acceptability of gene therapy for cancer treatment will create lucrative opportunities for cancer gene therapy market players. For instance, in August 2017, the US Food and Drug Administration (USFDA) approved an innovative treatment for children suffering from acute lymphoblastic leukemia. This gene therapy, “tisagenlecleucel (Kymriah™)”, is the first to be approved for cancer by the USFDA.
Gene therapy is one of the conceivable treatments suitable to the senior population with low to intermediate risk, according to respondents. In the U.S., cancer gene therapy is widely accepted. As a result, experts have emphasized that cancer gene therapy is deemed safe in the older population, and that the danger associated with gene therapy is minimal.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich Factors Are Restraining The Demand For Cancer Gene Therapy?
The high costs associated with gene therapy, along with a detrimental immune response are expected to impede the growth in the cancer gene therapy market during the forecast period.
The availability of other cancer treatment types such as chemotherapy and surgery is expected to limit sales. Viruses are the most efficient biological vectors for delivering genes to target cells. Due to safety concerns, non-viral vector delivery systems could be used as a safer alternative.
The shortage of qualified medical professionals for cancer gene therapy in developing countries can hinder the growth of the global cancer gene therapy market.
According to government data and Indian medical association, less than 1,600 oncologists are treating an estimated 1 million cancer patients in the country, with a 20% increase in cancer cases by the end of the decade.
Country-wise Insights
What is the U.S. Cancer Gene Therapy Market Outlook?
“Rising Awareness Regarding DNA Therapy for Cancer in the U.S. Will Augment Growth”
The U.S. dominated the North America cancer gene therapy market, holding 96.8% of the total market share in 2021, and the trend is expected to continue over the assessment period.
Breast cancer is one of the most frequent diseases in women worldwide, according to the Centers for Disease Control and Prevention (CDC), and it remains the second-largest cause of cancer death in women worldwide, fuelling the expansion of the cancer gene therapy industry. With a high prevalence of cancer in the country, the U.S. market is set to expand at a lucrative rate throughout assessment period.
Why is the China Cancer Gene Therapy Market Considered Lucrative?
“Increasing Adoption of Genetic Mutation Lung Cancer Treatment in China Will Boost Sales”
Sales in China are set to account for 32.3% of the East Asia cancer gene therapy market by 2032. The 'Regulations on the Management of Clinical Application of New Biomedical Technologies' and 'Regulations on the Safety Management of Biotechnology Research and Development' have been drafted by China's national health, scientific, and technology agencies.
The purpose of improving the rules and regulations is to create a more reasonable supervisory mechanism, strengthen supervision, increase legal responsibility, and encourage healthy development of biotechnology research, applications, and related businesses. Such developments are expected to bode well for the market over the forecast period.
What is Driving the Germany Cancer Gene Therapy Market?
“Increasing Demand for Gene Targeted Chemotherapy in Germany Will Steer Sales”
Demand in Germany is projected to increase at a CAGR of 11.9% during the forecast period. Manufacturers, healthcare professionals, and patients are hopeful as regulators create a defined path for speedy access to novel cancer gene therapies.
Players, on the other hand, are analysing the new medicines' added benefits. In the realm of gene treatments, major advancements are expected in the forthcoming years, thereby fueling sales in Germany.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-Wise Insights
Which Cancer Gene Therapy is Driving the Market?
“Demand for Oncolytic Virotherapy Will Gain Traction”
Based on therapy, the oncolytic virotherapy accounted for about 49.3% of the total market share in 2021. Sales in this segment are expected to increase at a 9.5% CAGR over the forecast period.
Oncolytic virus therapy is a promising new therapeutic approach for cancer treatment that has recently been identified. An oncolytic virus is a genetically designed or naturally occurring virus that may selectively reproduce in cancer cells and kill them while causing no harm to normal tissues. Oncolytic virus therapy differs from gene therapy in that it exploits the virus as an active pharmacological reagent rather than just a carrier for transgene delivery.
Which Indication Category is Leading the Cancer Gene Therapy Market?
“Sales of Cancer Gene Therapy for Breast Cancer to Remain High”
In terms of indication, the breast cancer segment held about 24.5% of the total market share in 2021, and is expected to expand at a 9.7% CAGR over the forecast period. Various governments in underdeveloped nations are taking steps to stimulate research efforts aimed at producing cancer gene therapy and treatment plans to lower mortality and morbidity rates, which will drive growth in the cancer gene therapy market over the forecast period.
Which Service Provider Benefits the Most in the Cancer Gene Therapy Market?
“Adoption of Cancer Gene Therapy in Hospitals Will Increase”
By service provider, the hospitals segment will expand at a 9.3% CAGR over the assessment period. The presence of trained providers, as well as institutional facilities equipped with treatment options are some factors expected to drive sales in this segment in the forthcoming years.
Moreover, the availability of reimbursement plans for gene therapy will continue pushing sales over the forecast period.
Competitive Landscape
Leading cancer gene therapy manufacturers are focusing on technological advancements in order to increase revenue and expand their footprint in emerging markets through acquisitions, partnerships, and collaborations.
For instance:
- In Sept 2021, Adaptimmune partnered with Genentech to develop allogeneic cell therapies indicated for multiple cancers.
- In June 2021, Eisai and Bristol Myers Squibb agreed to collaborate on the development and commercialization of Eisai's ADC, MORAb-202, for advanced solid malignancies.
- In June 2021, GSK and iTeos Therapeutics collaborated to develop EOS-448, an anti-TIGIT monoclonal antibody that had previously been approved in phase 1 for advanced solid malignancies.
Report Scope
|
Attribute |
Details |
|
Estimated Market Size (2022) |
US$ 2 Bn |
|
Projected Market Valuation (2032) |
US$ 5.3 Bn |
|
Value-based CAGR (2022-2032) |
10.1% |
|
Forecast Period |
2022-2032 |
|
Historical Data Available for |
2017-2021 |
|
Market Analysis |
US$ Bn for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
|
Key Countries Covered |
The U.S., Canada, Brazil, Mexico, Argentina, Germany, the U.K., France, Italy, Spain, Russia, Poland, Georgia China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, GCC Countries, Turkey, and South Africa |
|
Key Market Segments Covered |
Therapy, Indication, Service Provider, and Region |
|
Key Companies Profiled |
|
Key Market Segments Covered in Cancer Gene Therapy Industry Research
By Therapy:
- Gene Induced Immunotherapy
- Oncolytic Virotherapy
- Gene Transfer
- Others
By Indication:
- Breast Cancer
- Ovarian Cancer
- Liver Cancer
- Pancreatic Cancer
- Lung Cancer
- Prostate Cancer
By Service Provider:
- Hospitals
- Clinical Research Laboratory
- Oncology institutes
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
Frequently Asked Questions
How much is the cancer gene therapy market currently worth?
The global cancer gene therapy market is forecast to reach US$ 2 Bn in 2022 and is set to expand 2.6X over the forecast period.
What is the sales forecast for cancer gene therapy through 2032?
The cancer gene therapy market is expected to reach US$ 5.3 Bn by end of 2032 at a CAGR of 10.1%
What are the key trends shaping the cancer gene therapy market?
Key trends expected to drive sales in the market include increasing prevalence of cancer, rising awareness about healthcare practices among consumers, and an increase in the adoption of cancer gene therapy.
What are the restraints affecting the cancer gene therapy market?
The key restraints affecting the cancer gene therapy market are the presence of alternatives to cancer gene therapy, the high cost involved in cancer gene therapy, and the shortage of skilled professionals.
Which region has the highest market share in the global cancer gene therapy market?
North America held the highest market share of 52.8% by value in 2021 in the global cancer gene therapy market.
Which are the top 5 countries driving demand for cancer gene therapy?
The U.S., the U.K., Germany, France, and Japan are the top five countries that are expected to drive demand in the cancer gene therapy market.
Which are the key manufacturers of the cancer gene therapy market?
Merck KGaA, Novartis AG, AstraZeneca Plc. BIOCAD, Crinetics Pharmaceuticals, Inc., EffRx Pharmaceuticals S.A., Euroscreen S.A., Vicore Pharma AB, Amgen, Bristol-Myers Squibb, Cell Genesys Inc., Adaptimmune Therapeutics plc., Achieve Life Science Inc., BioCanCell Ltd., Genelux Corporation, Advantagene Inc., GenVec Inc., GlaxoSmithKline PLC, Amgen Inc. are the key manufacturers in this market.
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Technology Roadmap 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Success Factors 4.1. Technology Assessment 4.2. Disease Epidemiology 4.3. Regulatory Landscape 4.4. Reimbursement Outlook 4.5. Key Marketing & Promotional Strategies Adopted By Companies 4.6. PESTLE Analysis 4.7. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Rise in Healthcare Spending 5.1.3. Global Expenditure on Healthcare Infrastructure 5.2. Forecast Factors - Relevance & Impact 5.2.1. Mergers and Acquisitions 5.2.2. Disease Prevalence and Growth 5.2.3. R&D for Cancer Gene Therapy 5.2.4. Technological Advancements 5.2.5. Regulatory Framework 5.2.6. Reimbursement Policies 5.2.7. Prevalence of Geriatric Age Group 5.2.8. Global Burden of Cancer 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. COVID-19 and Impact Analysis 6.1.1. Revenue By Therapy 6.1.2. Revenue By Indication 6.1.3. Revenue By Service Provider 6.1.4. Revenue By Country 6.2. 2021 Market Scenario 7. Global Market Demand (in Value or Size in US$ Bn) Analysis 2017–2021 and Forecast, 2022–2032 7.1. Historical Market Value (US$ Bn) Analysis, 2017–2021 7.2. Current and Future Market Value (US$ Bn) Projections, 2022–2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2017–2021 and Forecast 2022–2032, By Therapy 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Bn) Trend Analysis, By Therapy, 2017–2021 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Therapy, 2022–2032 8.3.1. Gene Induced Immunotherapy 8.3.2. Oncolytic Virotherapy 8.3.3. Gene Transfer 8.3.4. Others 8.4. Market Attractiveness Analysis By Therapy 9. Global Market Analysis 2017–2021 and Forecast 2022–2032, By Indication 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Bn) Trend Analysis, By Indication, 2017–2021 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Indication, 2022–2032 9.3.1. Breast Cancer 9.3.2. Ovarian Cancer 9.3.3. Liver Cancer 9.3.4. Pancreatic Cancer 9.3.5. Lung Cancer 9.3.6. Prostate Cancer 9.4. Market Attractiveness Analysis By Indication 10. Global Market Analysis 2017–2021 and Forecast 2022–2032, By Service Provider 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Bn) Trend Analysis, By Service Provider, 2017–2021 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By Service Provider, 2022–2032 10.3.1. Hospitals 10.3.2. Clinical Research Laboratory 10.3.3. Oncology institutes 10.4. Market Attractiveness Analysis By Service Provider 11. Global Market Analysis 2017–2021 and Forecast 2022–2032, by Region 11.1. Introduction 11.2. Historical Market Size (US$ Bn) Analysis, By Region, 2017–2021 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2022–2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. East Asia 11.3.5. South Asia 11.3.6. Oceania 11.3.7. Middle East and Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Market Analysis 2017–2021 and Forecast 2022–2032 12.1. Introduction 12.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 12.3.1. By Country 12.3.1.1. U.S. 12.3.1.2. Canada 12.3.2. By Therapy 12.3.3. By Indication 12.3.4. By Service Provider 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Therapy 12.4.3. By Indication 12.4.4. By Service Provider 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. U.S. Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast by Market Taxonomy 12.8.1.2.1. By Therapy 12.8.1.2.2. By Indication 12.8.1.2.3. By Service Provider 12.8.2. Canada Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast by Market Taxonomy 12.8.2.2.1. By Therapy 12.8.2.2.2. By Indication 12.8.2.2.3. By Service Provider 13. Latin America Market Analysis 2017–2021 and Forecast 2022–2032 13.1. Introduction 13.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 13.3.1. By Country 13.3.1.1. Mexico 13.3.1.2. Brazil 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Therapy 13.3.3. By Indication 13.3.4. By Service Provider 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Therapy 13.4.3. By Indication 13.4.4. By Service Provider 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. Mexico Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast by Market Taxonomy 13.8.1.2.1. By Therapy 13.8.1.2.2. By Indication 13.8.1.2.3. By Service Provider 13.8.2. Brazil Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast by Market Taxonomy 13.8.2.2.1. By Therapy 13.8.2.2.2. By Indication 13.8.2.2.3. By Service Provider 13.8.3. Argentina Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast by Market Taxonomy 13.8.3.2.1. By Therapy 13.8.3.2.2. By Indication 13.8.3.2.3. By Service Provider 14. Europe Market Analysis 2017–2021 and Forecast 2022–2032 14.1. Introduction 14.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. U.K. 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Nordic Countries 14.3.1.8. Russia 14.3.1.9. Rest of Europe 14.3.2. By Therapy 14.3.3. By Indication 14.3.4. By Service Provider 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Therapy 14.4.3. By Indication 14.4.4. By Service Provider 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. Germany Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast by Market Taxonomy 14.8.1.2.1. By Therapy 14.8.1.2.2. By Indication 14.8.1.2.3. By Service Provider 14.8.2. Italy Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast by Market Taxonomy 14.8.2.2.1. By Therapy 14.8.2.2.2. By Indication 14.8.2.2.3. By Service Provider 14.8.3. France Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast by Market Taxonomy 14.8.3.2.1. By Therapy 14.8.3.2.2. By Indication 14.8.3.2.3. By Service Provider 14.8.4. U.K. Market Analysis 14.8.4.1. Introduction 14.8.4.2. Market Analysis and Forecast by Market Taxonomy 14.8.4.2.1. By Therapy 14.8.4.2.2. By Indication 14.8.4.2.3. By Service Provider 14.8.5. Spain Market Analysis 14.8.5.1. Introduction 14.8.5.2. Market Analysis and Forecast by Market Taxonomy 14.8.5.2.1. By Therapy 14.8.5.2.2. By Indication 14.8.5.2.3. By Service Provider 14.8.6. BENELUX Market Analysis 14.8.6.1. Introduction 14.8.6.2. Market Analysis and Forecast by Market Taxonomy 14.8.6.2.1. By Therapy 14.8.6.2.2. By Indication 14.8.6.2.3. By Service Provider 14.8.7. Nordic Countries Contact Lenses Market Analysis 14.8.7.1. Introduction 14.8.7.2. Market Analysis and Forecast by Market Taxonomy 14.8.7.2.1. By Therapy 14.8.7.2.2. By Indication 14.8.7.2.3. By Service Provider 14.8.8. Russia Market Analysis 14.8.8.1. Introduction 14.8.8.2. Market Analysis and Forecast by Market Taxonomy 14.8.8.2.1. By Therapy 14.8.8.2.2. By Indication 14.8.8.2.3. By Service Provider 15. East Asia Market Analysis 2017–2021 and Forecast 2022–2032 15.1. Introduction 15.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 15.3.1. By Country 15.3.1.1. China 15.3.1.2. Japan 15.3.1.3. South Korea 15.3.2. By Therapy 15.3.3. By Indication 15.3.4. By Service Provider 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Therapy 15.4.3. By Indication 15.4.4. By Service Provider 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. China Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Therapy 15.8.1.2.2. By Indication 15.8.1.2.3. By Service Provider 15.8.2. Japan Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Therapy 15.8.2.2.2. By Indication 15.8.2.2.3. By Service Provider 15.8.3. South Korea Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast by Market Taxonomy 15.8.3.2.1. By Therapy 15.8.3.2.2. By Indication 15.8.3.2.3. By Service Provider 16. South Asia Market Analysis 2017–2021 and Forecast 2022–2032 16.1. Introduction 16.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Indonesia 16.3.1.3. Malaysia 16.3.1.4. Philippines 16.3.1.5. Thailand 16.3.1.6. Vietnam 16.3.1.7. Rest of South Asia 16.3.2. By Therapy 16.3.3. By Indication 16.3.4. By Service Provider 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Therapy 16.4.3. By Indication 16.4.4. By Service Provider 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. India Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Therapy 16.8.1.2.2. By Indication 16.8.1.2.3. By Service Provider 16.8.2. Indonesia Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Therapy 16.8.2.2.2. By Indication 16.8.2.2.3. By Service Provider 16.8.3. Malaysia Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Therapy 16.8.3.2.2. By Indication 16.8.3.2.3. By Service Provider 16.8.4. Philippines Market Analysis 16.8.4.1. Introduction 16.8.4.2. Market Analysis and Forecast by Market Taxonomy 16.8.4.2.1. By Therapy 16.8.4.2.2. By Indication 16.8.4.2.3. By Service Provider 16.8.5. Thailand Market Analysis 16.8.5.1. Introduction 16.8.5.2. Market Analysis and Forecast by Market Taxonomy 16.8.5.2.1. By Therapy 16.8.5.2.2. By Indication 16.8.5.2.3. By Service Provider 16.8.6. Vietnam Market Analysis 16.8.6.1. Introduction 16.8.6.2. Market Analysis and Forecast by Market Taxonomy 16.8.6.2.1. By Therapy 16.8.6.2.2. By Indication 16.8.6.2.3. By Service Provider 17. Oceania Market 2012-2021 and Forecast 2022-2032 17.1. Introduction 17.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. By Therapy 17.3.3. By Indication 17.3.4. By Service Provider 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Therapy 17.4.3. By Indication 17.4.4. By Service Provider 17.5. Market Trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. Australia Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Therapy 17.8.1.2.2. By Indication 17.8.1.2.3. By Service Provider 17.8.2. New Zealand Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Therapy 17.8.2.2.2. By Indication 17.8.2.2.3. By Service Provider 18. Middle East and Africa (MEA) Market Analysis 2017–2021 and Forecast 2022–2032 18.1. Introduction 18.2. Historical Market Size (US$ Bn) Analysis By Market Taxonomy, 2017–2021 18.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2022–2032 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Israel 18.3.1.3. Turkey 18.3.1.4. South Africa 18.3.1.5. North Africa 18.3.1.6. Rest of Middle East and Africa 18.3.2. By Therapy 18.3.3. By Indication 18.3.4. By Service Provider 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Therapy 18.4.3. By Indication 18.4.4. By Service Provider 18.5. Market Trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. GCC Countries Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Therapy 18.8.1.2.2. By Indication 18.8.1.2.3. By Service Provider 18.8.2. Israel Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Therapy 18.8.2.2.2. By Indication 18.8.2.2.3. By Service Provider 18.8.3. Turkey Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Therapy 18.8.3.2.2. By Indication 18.8.3.2.3. By Service Provider 18.8.4. South Africa Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Therapy 18.8.4.2.2. By Indication 18.8.4.2.3. By Service Provider 18.8.5. North Africa Market Analysis 18.8.5.1. Introduction 18.8.5.2. Market Analysis and Forecast by Market Taxonomy 18.8.5.2.1. By Therapy 18.8.5.2.2. By Indication 18.8.5.2.3. By Service Provider 19. Market Structure Analysis 19.1. Market Analysis by Tier of Companies 19.2. Market Share Analysis of Top Players 19.3. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Benchmarking 20.3. Competition Deep Dive 20.3.1. Merck KGaA 20.3.1.1. Overview 20.3.1.2. Product Portfolio 20.3.1.3. Profitability by Market Segments (Product/Channel/Region) 20.3.1.4. Sales Footprint 20.3.1.5. Key Financials 20.3.1.6. SWOT Analysis 20.3.1.7. Strategy Overview 20.3.2. Novartis AG 20.3.2.1. Overview 20.3.2.2. Product Portfolio 20.3.2.3. Profitability by Market Segments (Product/Channel/Region) 20.3.2.4. Sales Footprint 20.3.2.5. Key Financials 20.3.2.6. SWOT Analysis 20.3.2.7. Strategy Overview 20.3.3. AstraZeneca Plc 20.3.3.1. Overview 20.3.3.2. Product Portfolio 20.3.3.3. Profitability by Market Segments (Product/Channel/Region) 20.3.3.4. Sales Footprint 20.3.3.5. Key Financials 20.3.3.6. SWOT Analysis 20.3.3.7. Strategy Overview 20.3.4. BIOCAD 20.3.4.1. Overview 20.3.4.2. Product Portfolio 20.3.4.3. Profitability by Market Segments (Product/Channel/Region) 20.3.4.4. Sales Footprint 20.3.4.5. Key Financials 20.3.4.6. SWOT Analysis 20.3.4.7. Strategy Overview 20.3.5. Crinetics Pharmaceuticals, Inc. 20.3.5.1. Overview 20.3.5.2. Product Portfolio 20.3.5.3. Profitability by Market Segments (Product/Channel/Region) 20.3.5.4. Sales Footprint 20.3.5.5. Key Financials 20.3.5.6. SWOT Analysis 20.3.5.7. Strategy Overview 20.3.6. EffRx Pharmaceuticals S.A. 20.3.6.1. Overview 20.3.6.2. Product Portfolio 20.3.6.3. Profitability by Market Segments (Product/Channel/Region) 20.3.6.4. Sales Footprint 20.3.6.5. Key Financials 20.3.6.6. SWOT Analysis 20.3.6.7. Strategy Overview 20.3.7. Euroscreen S.A. 20.3.7.1. Overview 20.3.7.2. Product Portfolio 20.3.7.3. Profitability by Market Segments (Product/Channel/Region) 20.3.7.4. Sales Footprint 20.3.7.5. Key Financials 20.3.7.6. SWOT Analysis 20.3.7.7. Strategy Overview 20.3.8. Vicore Pharma AB 20.3.8.1. Overview 20.3.8.2. Product Portfolio 20.3.8.3. Profitability by Market Segments (Product/Channel/Region) 20.3.8.4. Sales Footprint 20.3.8.5. Key Financials 20.3.8.6. SWOT Analysis 20.3.8.7. Strategy Overview 20.3.9. Amgen 20.3.9.1. Overview 20.3.9.2. Product Portfolio 20.3.9.3. Profitability by Market Segments (Product/Channel/Region) 20.3.9.4. Sales Footprint 20.3.9.5. Key Financials 20.3.9.6. SWOT Analysis 20.3.9.7. Strategy Overview 20.3.10. Bristol-Myers Squibb 20.3.10.1. Overview 20.3.10.2. Product Portfolio 20.3.10.3. Profitability by Market Segments (Product/Channel/Region) 20.3.10.4. Sales Footprint 20.3.10.5. Key Financials 20.3.10.6. SWOT Analysis 20.3.10.7. Strategy Overview 20.3.11. Cell Genesys Inc. 20.3.11.1. Overview 20.3.11.2. Product Portfolio 20.3.11.3. Profitability by Market Segments (Product/Channel/Region) 20.3.11.4. Sales Footprint 20.3.11.5. Key Financials 20.3.11.6. SWOT Analysis 20.3.11.7. Strategy Overview 20.3.12. Adaptimmune Therapeutics plc 20.3.12.1. Overview 20.3.12.2. Product Portfolio 20.3.12.3. Profitability by Market Segments (Product/Channel/Region) 20.3.12.4. Sales Footprint 20.3.12.5. Key Financials 20.3.12.6. SWOT Analysis 20.3.12.7. Strategy Overview 20.3.13. Achieve Life Science Inc. 20.3.13.1. Overview 20.3.13.2. Product Portfolio 20.3.13.3. Profitability by Market Segments (Product/Channel/Region) 20.3.13.4. Sales Footprint 20.3.13.5. Key Financials 20.3.13.6. SWOT Analysis 20.3.13.7. Strategy Overview 20.3.14. BioCanCell Ltd. 20.3.14.1. Overview 20.3.14.2. Product Portfolio 20.3.14.3. Profitability by Market Segments (Product/Channel/Region) 20.3.14.4. Sales Footprint 20.3.14.5. Key Financials 20.3.14.6. SWOT Analysis 20.3.14.7. Strategy Overview 20.3.15. Genelux Corporation 20.3.15.1. Overview 20.3.15.2. Product Portfolio 20.3.15.3. Profitability by Market Segments (Product/Channel/Region) 20.3.15.4. Sales Footprint 20.3.15.5. Key Financials 20.3.15.6. SWOT Analysis 20.3.15.7. Strategy Overview 20.3.16. Advantagene Inc., 20.3.16.1. Overview 20.3.16.2. Product Portfolio 20.3.16.3. Profitability by Market Segments (Product/Channel/Region) 20.3.16.4. Sales Footprint 20.3.16.5. Key Financials 20.3.16.6. SWOT Analysis 20.3.16.7. Strategy Overview 20.3.17. GenVec Inc. 20.3.17.1. Overview 20.3.17.2. Product Portfolio 20.3.17.3. Profitability by Market Segments (Product/Channel/Region) 20.3.17.4. Sales Footprint 20.3.17.5. Key Financials 20.3.17.6. SWOT Analysis 20.3.17.7. Strategy Overview 20.3.18. Glaxosmithkline PLC 20.3.18.1. Overview 20.3.18.2. Product Portfolio 20.3.18.3. Profitability by Market Segments (Product/Channel/Region) 20.3.18.4. Sales Footprint 20.3.18.5. Key Financials 20.3.18.6. SWOT Analysis 20.3.18.7. Strategy Overview 20.3.19. Amgen Inc. 20.3.19.1. Overview 20.3.19.2. Product Portfolio 20.3.19.3. Profitability by Market Segments (Product/Channel/Region) 20.3.19.4. Sales Footprint 20.3.19.5. Key Financials 20.3.19.6. SWOT Analysis 20.3.19.7. Strategy Overview 21. Assumptions and Acronyms Used 22. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Bn) Forecast by Region, 2017 & 2032 Table 02: Global Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032 Table 03: Global Market Value (US$ Bn) Forecast by Indication, 2017 & 2032 Table 04: Global Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032 Table 05: North America Market Value (US$ Bn) Forecast by Country, 2017 & 2032 Table 06: North America Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032 Table 07: North America Market Value (US$ Bn) Forecast by Indication, 2017 & 2032 Table 08: North America Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032 Table 09: Latin America Market Value (US$ Bn) Forecast by Country, 2017 & 2032 Table 10: Latin America Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032 Table 11: Latin America Market Value (US$ Bn) Forecast by Indication, 2017 & 2032 Table 12: Latin America Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032 Table 13: Europe Market Value (US$ Bn) Forecast by Country, 2017 & 2032 Table 14: Europe Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032 Table 15: Europe Market Value (US$ Bn) Forecast by Indication, 2017 & 2032 Table 16: Europe Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032 Table 17: East Asia Market Value (US$ Bn) Forecast by Country, 2017 & 2032 Table 18: East Asia Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032 Table 19: East Asia Market Value (US$ Bn) Forecast by Indication, 2017 & 2032 Table 20: East Asia Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032 Table 21: South Asia Market Value (US$ Bn) Forecast by Country, 2017 & 2032 Table 22: South Asia Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032 Table 23: South Asia Market Value (US$ Bn) Forecast by Indication, 2017 & 2032 Table 24: South Asia Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032 Table 25: Oceania Market Value (US$ Bn) Forecast by Country, 2017 & 2032 Table 26: Oceania Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032 Table 27: Oceania Market Value (US$ Bn) Forecast by Indication, 2017 & 2032 Table 28: Oceania Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032 Table 29: MEA Market Value (US$ Bn) Forecast by Country, 2017 & 2032 Table 30: MEA Market Value (US$ Bn) Forecast by Therapy, 2017 & 2032 Table 31: MEA Market Value (US$ Bn) Forecast by Indication, 2017 & 2032 Table 32: MEA Market Value (US$ Bn) Forecast by Service Provider, 2017 & 2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Value (US$ Bn) by Therapy, 2022 & 2032 Figure 02: Global Market Value (US$ Bn) by Indication, 2022 & 2032 Figure 03: Global Market Value (US$ Bn) by Service Provider, 2022 & 2032 Figure 04: Global Market Value (US$ Bn) by Region, 2022 & 2032 Figure 05: Global Market Value (US$ Bn) Analysis by Region, 2017 & 2032 Figure 06: Global Market Value Share (%) and BPS Analysis by Region, 2022 & 2032 Figure 07: Global Market Y-o-Y Growth (%) Projections by Region, 2022-2032 Figure 08: Global Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032 Figure 09: Global Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032 Figure 10: Global Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032 Figure 11: Global Market Value (US$ Bn) Analysis by Indication, 2017 & 2032 Figure 12: Global Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032 Figure 13: Global Market Y-o-Y Growth (%) Projections by Indication, 2022-2032 Figure 14: Global Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032 Figure 15: Global Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032 Figure 16: Global Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032 Figure 17: Global Market Attractiveness by Therapy, 2022-2032 Figure 18: Global Market Attractiveness by Indication, 2022-2032 Figure 19: Global Market Attractiveness by Service Provider, 2022-2032 Figure 20: Global Market Attractiveness by Region, 2022-2032 Figure 21: North America Market Value (US$ Bn) by Therapy, 2022 & 2032 Figure 22: North America Market Value (US$ Bn) by Indication, 2022 & 2032 Figure 23: North America Market Value (US$ Bn) by Service Provider, 2022 & 2032 Figure 24: North America Market Value (US$ Bn) by Country, 2022 & 2032 Figure 25: North America Market Value (US$ Bn) Analysis by Country, 2017 & 2032 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2022 & 2032 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 28: North America Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032 Figure 29: North America Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032 Figure 30: North America Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032 Figure 31: North America Market Value (US$ Bn) Analysis by Indication, 2017 & 2032 Figure 32: North America Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032 Figure 33: North America Market Y-o-Y Growth (%) Projections by Indication, 2022-2032 Figure 34: North America Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032 Figure 35: North America Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032 Figure 36: North America Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032 Figure 37: North America Market Attractiveness by Therapy, 2022-2032 Figure 38: North America Market Attractiveness by Indication, 2022-2032 Figure 39: North America Market Attractiveness by Service Provider, 2022-2032 Figure 40: North America Market Attractiveness by Country, 2022-2032 Figure 41: Latin America Market Value (US$ Bn) by Therapy, 2022 & 2032 Figure 42: Latin America Market Value (US$ Bn) by Indication, 2022 & 2032 Figure 43: Latin America Market Value (US$ Bn) by Service Provider, 2022 & 2032 Figure 44: Latin America Market Value (US$ Bn) by Country, 2022 & 2032 Figure 45: Latin America Market Value (US$ Bn) Analysis by Country, 2017 & 2032 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2022 & 2032 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 48: Latin America Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032 Figure 51: Latin America Market Value (US$ Bn) Analysis by Indication, 2017 & 2032 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Indication, 2022-2032 Figure 54: Latin America Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032 Figure 57: Latin America Market Attractiveness by Therapy, 2022-2032 Figure 58: Latin America Market Attractiveness by Indication, 2022-2032 Figure 59: Latin America Market Attractiveness by Service Provider, 2022-2032 Figure 60: Latin America Market Attractiveness by Country, 2022-2032 Figure 61: Europe Market Value (US$ Bn) by Therapy, 2022 & 2032 Figure 62: Europe Market Value (US$ Bn) by Indication, 2022 & 2032 Figure 63: Europe Market Value (US$ Bn) by Service Provider, 2022 & 2032 Figure 64: Europe Market Value (US$ Bn) by Country, 2022 & 2032 Figure 65: Europe Market Value (US$ Bn) Analysis by Country, 2017 & 2032 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2022 & 2032 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 68: Europe Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032 Figure 69: Europe Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032 Figure 71: Europe Market Value (US$ Bn) Analysis by Indication, 2017 & 2032 Figure 72: Europe Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Indication, 2022-2032 Figure 74: Europe Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032 Figure 75: Europe Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032 Figure 77: Europe Market Attractiveness by Therapy, 2022-2032 Figure 78: Europe Market Attractiveness by Indication, 2022-2032 Figure 79: Europe Market Attractiveness by Service Provider, 2022-2032 Figure 80: Europe Market Attractiveness by Country, 2022-2032 Figure 81: East Asia Market Value (US$ Bn) by Therapy, 2022 & 2032 Figure 82: East Asia Market Value (US$ Bn) by Indication, 2022 & 2032 Figure 83: East Asia Market Value (US$ Bn) by Service Provider, 2022 & 2032 Figure 84: East Asia Market Value (US$ Bn) by Country, 2022 & 2032 Figure 85: East Asia Market Value (US$ Bn) Analysis by Country, 2017 & 2032 Figure 86: East Asia Market Value Share (%) and BPS Analysis by Country, 2022 & 2032 Figure 87: East Asia Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 88: East Asia Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032 Figure 89: East Asia Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032 Figure 90: East Asia Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032 Figure 91: East Asia Market Value (US$ Bn) Analysis by Indication, 2017 & 2032 Figure 92: East Asia Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032 Figure 93: East Asia Market Y-o-Y Growth (%) Projections by Indication, 2022-2032 Figure 94: East Asia Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032 Figure 95: East Asia Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032 Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032 Figure 97: East Asia Market Attractiveness by Therapy, 2022-2032 Figure 98: East Asia Market Attractiveness by Indication, 2022-2032 Figure 99: East Asia Market Attractiveness by Service Provider, 2022-2032 Figure 100: East Asia Market Attractiveness by Country, 2022-2032 Figure 101: South Asia Market Value (US$ Bn) by Therapy, 2022 & 2032 Figure 102: South Asia Market Value (US$ Bn) by Indication, 2022 & 2032 Figure 103: South Asia Market Value (US$ Bn) by Service Provider, 2022 & 2032 Figure 104: South Asia Market Value (US$ Bn) by Country, 2022 & 2032 Figure 105: South Asia Market Value (US$ Bn) Analysis by Country, 2017 & 2032 Figure 106: South Asia Market Value Share (%) and BPS Analysis by Country, 2022 & 2032 Figure 107: South Asia Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 108: South Asia Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032 Figure 109: South Asia Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032 Figure 110: South Asia Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032 Figure 111: South Asia Market Value (US$ Bn) Analysis by Indication, 2017 & 2032 Figure 112: South Asia Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032 Figure 113: South Asia Market Y-o-Y Growth (%) Projections by Indication, 2022-2032 Figure 114: South Asia Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032 Figure 115: South Asia Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032 Figure 116: South Asia Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032 Figure 117: South Asia Market Attractiveness by Therapy, 2022-2032 Figure 118: South Asia Market Attractiveness by Indication, 2022-2032 Figure 119: South Asia Market Attractiveness by Service Provider, 2022-2032 Figure 120: South Asia Market Attractiveness by Country, 2022-2032 Figure 121: Oceania Market Value (US$ Bn) by Therapy, 2022 & 2032 Figure 122: Oceania Market Value (US$ Bn) by Indication, 2022 & 2032 Figure 123: Oceania Market Value (US$ Bn) by Service Provider, 2022 & 2032 Figure 124: Oceania Market Value (US$ Bn) by Country, 2022 & 2032 Figure 125: Oceania Market Value (US$ Bn) Analysis by Country, 2017 & 2032 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2022 & 2032 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 128: Oceania Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032 Figure 131: Oceania Market Value (US$ Bn) Analysis by Indication, 2017 & 2032 Figure 132: Oceania Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Indication, 2022-2032 Figure 134: Oceania Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032 Figure 135: Oceania Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032 Figure 137: Oceania Market Attractiveness by Therapy, 2022-2032 Figure 138: Oceania Market Attractiveness by Indication, 2022-2032 Figure 139: Oceania Market Attractiveness by Service Provider, 2022-2032 Figure 140: Oceania Market Attractiveness by Country, 2022-2032 Figure 141: MEA Market Value (US$ Bn) by Therapy, 2022 & 2032 Figure 142: MEA Market Value (US$ Bn) by Indication, 2022 & 2032 Figure 143: MEA Market Value (US$ Bn) by Service Provider, 2022 & 2032 Figure 144: MEA Market Value (US$ Bn) by Country, 2022 & 2032 Figure 145: MEA Market Value (US$ Bn) Analysis by Country, 2017 & 2032 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2022 & 2032 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2022-2032 Figure 148: MEA Market Value (US$ Bn) Analysis by Therapy, 2017 & 2032 Figure 149: MEA Market Value Share (%) and BPS Analysis by Therapy, 2022 & 2032 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Therapy, 2022-2032 Figure 151: MEA Market Value (US$ Bn) Analysis by Indication, 2017 & 2032 Figure 152: MEA Market Value Share (%) and BPS Analysis by Indication, 2022 & 2032 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Indication, 2022-2032 Figure 154: MEA Market Value (US$ Bn) Analysis by Service Provider, 2017 & 2032 Figure 155: MEA Market Value Share (%) and BPS Analysis by Service Provider, 2022 & 2032 Figure 156: MEA Market Y-o-Y Growth (%) Projections by Service Provider, 2022-2032 Figure 157: MEA Market Attractiveness by Therapy, 2022-2032 Figure 158: MEA Market Attractiveness by Indication, 2022-2032 Figure 159: MEA Market Attractiveness by Service Provider, 2022-2032 Figure 160: MEA Market Attractiveness by Country, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
